Assessment of cardiotoxicity with cardiac biomarkers in cancer patients

[1]  J. Soria,et al.  Frequency and management of troponin I elevation in patients treated with molecular targeted therapies in phase I trials , 2012, Investigational New Drugs.

[2]  R. Wachter,et al.  Serial NT-proBNP measurements for risk stratification of patients with decompensated heart failure , 2010, Herz.

[3]  F. Veglia,et al.  Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  G. Mantovani,et al.  Protective effects of the angiotensin II receptor blocker telmisartan on epirubicin-induced inflammation, oxidative stress, and early ventricular impairment. , 2010, American heart journal.

[5]  J. Horáček,et al.  The use of cardiac biomarkers in detection of cardiotoxicity associated with conventional and high-dose chemotherapy for acute leukemia. , 2010, Experimental oncology.

[6]  F. Veglia,et al.  Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. , 2010, Journal of the American College of Cardiology.

[7]  C. Angermann,et al.  Biomarkers in Heart Failure – Better than History or Echocardiography? , 2009, Herz.

[8]  H. Katus,et al.  Troponins and High-Sensitivity Troponins as Markers of Necrosis in CAD and Heart Failure , 2009, Herz.

[9]  J. Gietema,et al.  Vascular damage in testicular cancer patients: a study on endothelial activation by bleomycin and cisplatin in vitro. , 2009, Oncology reports.

[10]  E. Yeh,et al.  Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. , 2009, Journal of the American College of Cardiology.

[11]  A. Elghandour,et al.  Human heart-type fatty acid-binding protein as an early diagnostic marker of doxorubicin cardiac toxicity , 2009, Hematology Reviews.

[12]  M. Panteghini,et al.  Biochemical markers for prediction of chemotherapy-induced cardiotoxicity: systematic review of the literature and recommendations for use. , 2008, American journal of clinical pathology.

[13]  Wendy Leisenring,et al.  Cause-specific late mortality among 5-year survivors of childhood cancer: the Childhood Cancer Survivor Study. , 2008, Journal of the National Cancer Institute.

[14]  M. Kalmanti,et al.  Troponins and natriuretic peptides in the monitoring of anthracycline cardiotoxicity , 2008, Pediatric blood & cancer.

[15]  V. Zadnik,et al.  Cardiac toxicity of high-dose cyclophosphamide and melphalan in patients with multiple myeloma treated with tandem autologous hematopoietic stem cell transplantation , 2008, International journal of hematology.

[16]  S. Palmer,et al.  Cardiovascular risk in long‐term survivors of testicular cancer , 2008, Cancer.

[17]  P. O'Brien.  Cardiac troponin is the most effective translational safety biomarker for myocardial injury in cardiotoxicity. , 2008, Toxicology.

[18]  B. Hesse,et al.  BNP cannot replace gated equilibrium radionuclide ventriculography in monitoring of anthracycline-induced cardiotoxity. , 2008, International journal of cardiology.

[19]  S. Swain,et al.  Cardiac Toxicity in Breast Cancer Survivors: Review of Potential Cardiac Problems , 2008, Clinical Cancer Research.

[20]  A. Hall,et al.  Heart-type fatty acid-binding protein predicts long-term mortality after acute coronary syndrome and identifies high-risk patients across the range of troponin values. , 2007, Journal of the American College of Cardiology.

[21]  J. D. de Lemos,et al.  The skinny on fatty acid-binding protein. , 2007, Journal of the American College of Cardiology.

[22]  M. Somerfield,et al.  American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  Hermann Brenner,et al.  Recent cancer survival in Europe: a 2000-02 period analysis of EUROCARE-4 data. , 2007, The Lancet. Oncology.

[24]  G. Mantovani,et al.  Early epirubicin-induced myocardial dysfunction revealed by serial tissue Doppler echocardiography: correlation with inflammatory and oxidative stress markers. , 2007, The oncologist.

[25]  M. Štěrba,et al.  In vitro and in vivo examination of cardiac troponins as biochemical markers of drug-induced cardiotoxicity. , 2007, Toxicology.

[26]  Y. Genç,et al.  Early prediction of anthracycline induced cardiotoxicity , 2007, Acta paediatrica.

[27]  D. Atar,et al.  Mechanism of troponin elevations in patients with acute ischemic stroke. , 2007, The American journal of cardiology.

[28]  Giovanni Martinelli,et al.  Prevention of High-Dose Chemotherapy-Induced Cardiotoxicity in High-Risk Patients by Angiotensin-Converting Enzyme Inhibition , 2006, Circulation.

[29]  M. Sabatine,et al.  Prognostic Utility of Heart-Type Fatty Acid Binding Protein in Patients With Acute Coronary Syndromes , 2006, Circulation.

[30]  M. Panteghini.  The new definition of myocardial infarction and the impact of troponin determination on clinical practice. , 2006, International journal of cardiology.

[31]  E. Yeh.  Cardiotoxicity induced by chemotherapy and antibody therapy. , 2006, Annual review of medicine.

[32]  S. Lipshultz,et al.  Protecting against anthracycline‐induced myocardial damage: a review of the most promising strategies , 2005, British journal of haematology.

[33]  Harlan M Krumholz,et al.  ACC/AHA Clinical Performance Measures for Adults with Chronic Heart Failure: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Heart Failure Clinical Performance Measures): endorsed by the Heart Failure Society , 2005, Circulation.

[34]  G. Martinelli,et al.  N-terminal pro-B-type natriuretic peptide after high-dose chemotherapy: a marker predictive of cardiac dysfunction? , 2005, Clinical chemistry.

[35]  M. Štěrba,et al.  Troponin as a marker of myocardiac damage in drug-induced cardiotoxicity , 2005, Expert opinion on drug safety.

[36]  S. Aksöyek,et al.  cTnT can be a useful marker for early detection of anthracycline cardiotoxicity. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[37]  G. Specchia,et al.  Monitoring of cardiac function on the basis of serum troponin I levels in patients with acute leukemia treated with anthracyclines. , 2005, The Journal of laboratory and clinical medicine.

[38]  J. Goetze.  Biochemistry of pro-B-type natriuretic peptide-derived peptides: the endocrine heart revisited. , 2004, Clinical chemistry.

[39]  Michael S Ewer,et al.  Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. , 2004, Circulation.

[40]  G. Martinelli,et al.  Prognostic Value of Troponin I in Cardiac Risk Stratification of Cancer Patients Undergoing High-Dose Chemotherapy , 2004, Circulation.

[41]  J. Silber,et al.  Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  A. V. van Roon,et al.  Microalbuminuria, decreased fibrinolysis, and inflammation as early signs of atherosclerosis in long-term survivors of disseminated testicular cancer. , 2004, European journal of cancer.

[43]  A. Tiran,et al.  Prolonged monitoring of troponin T for the detection of anthracycline cardiotoxicity in adults with hematological malignancies , 2003, Annals of Hematology.

[44]  Giovanni Martinelli,et al.  Minor increases in plasma troponin I predict decreased left ventricular ejection fraction after high-dose chemotherapy. , 2003, Clinical chemistry.

[45]  G. Martinelli,et al.  Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[46]  B. Jensen,et al.  Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[47]  H. Hayakawa,et al.  Plasma levels of natriuretic peptides in relation to doxorubicin-induced cardiotoxicity and cardiac function in children with cancer. , 2001, Medical and pediatric oncology.

[48]  Shinobu Nakamura,et al.  Brain Natriuretic Peptide Is a Predictor of Anthracycline-Induced Cardiotoxicity , 2001, Acta Haematologica.

[49]  G. Martinelli,et al.  Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. , 2000, Journal of the American College of Cardiology.

[50]  D. Baumgart,et al.  Antiischämische Wirkung von Verapamil im Rahmen einer interventionellen Rekanalisation , 1999, Herz.

[51]  E. D. de Vries,et al.  Detection of anthracycline-induced cardiotoxicity. , 1999, Cancer treatment reviews.

[52]  J. Hartikainen,et al.  Natriuretic peptides as markers of cardiotoxicity during doxorubicin treatment for non‐Hodgkin's lymphoma , 1999, European journal of haematology.

[53]  J. Hartikainen,et al.  Acute neurohumoral and cardiovascular effects of idarubicin in leukemia patients , 1998, European journal of haematology.

[54]  R. Nagai,et al.  Elevated B-type natriuretic peptide levels after anthracycline administration. , 1998, American heart journal.

[55]  T. Helenius,et al.  Serum N-terminal atrial natriuretic peptide (NT-ANP) in the cardiac follow-up in children with cancer. , 1998, Medical and pediatric oncology.

[56]  S. Lipsitz,et al.  Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury. , 1997, Circulation.

[57]  R. Schwartz,et al.  Guidelines for cardiac monitoring of children during and after anthracycline therapy: report of the Cardiology Committee of the Childrens Cancer Study Group. , 1992, Pediatrics.

[58]  P. Dombernowsky,et al.  Epirubicin cardiotoxicity: a study of 135 patients with advanced breast cancer. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[59]  G. Hortobagyi,et al.  Doxorubicin‐induced congestive heart failure in adults , 1985, Cancer.

[60]  D. V. Von Hoff,et al.  Risk factors for doxorubicin-induced congestive heart failure. , 1979, Annals of internal medicine.

[61]  R. Arceci.  Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial , 2011 .

[62]  T. Eberlein.  Overall Survival and Cause-Specific Mortality of Patients With Stage T1a,bN0M0 Breast Carcinoma , 2009 .

[63]  L. Urban,et al.  Cardiac troponins--biochemical markers of cardiac toxicity after cytostatic therapy. , 2006, Neoplasma.

[64]  E. Olsen,et al.  Comparison of Circulating Levels of Interleukin-6 and Tumor Necrosis Factor-Alpha in Hypertrophic Cardiomyopathy and in Idiopathic Dilated Cardiomyopathy , 2004 .

[65]  A. Wolff,et al.  Predicting Cancer Therapy-Induced Cardiotoxicity , 2002, Drug safety.

[66]  ICHAEL,et al.  UNDERLYING CAUSES AND LONG-TERM SURVIVAL IN PATIENTS WITH INITIALLY UNEXPLAINED CARDIOMYOPATHY , 2000 .